Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18594725 | MODULATORS OF TNF-ALPHA ACTIVITY | March 2024 | February 2025 | Allow | 11 | 0 | 0 | Yes | No |
| 18441930 | ALLERGEN DESENSITIZATION METHOD | February 2024 | May 2025 | Allow | 15 | 1 | 0 | Yes | No |
| 18535520 | DEGRADANT COMPOUND IN A MEDICAMENT | December 2023 | December 2024 | Abandon | 12 | 1 | 1 | No | No |
| 18531082 | FORMULATIONS COMPRISING CARBACHOL AND BRIMONIDINE TO ENHANCE ANTI-PRESBYOPIA EFFECTS | December 2023 | February 2025 | Allow | 15 | 1 | 1 | Yes | No |
| 18500416 | OCULAR FORMULATIONS FOR DRUG-DELIVERY AND PROTECTION OF THE ANTERIOR SEGMENT OF THE EYE | November 2023 | April 2025 | Abandon | 17 | 1 | 0 | No | No |
| 18494341 | KETOROLAC TROMETHAMINE COMPOSITIONS FOR TREATING OR PREVENTING OCULAR PAIN | October 2023 | April 2025 | Abandon | 17 | 1 | 0 | No | No |
| 18471977 | MODULATORS OF TNF-ALPHA ACTIVITY | September 2023 | January 2024 | Allow | 4 | 0 | 1 | Yes | No |
| 18144771 | BROMODOMAIN INHIBITOR | May 2023 | March 2025 | Abandon | 22 | 0 | 1 | No | No |
| 18250921 | DEGRADANT COMPOUND IN A MEDICAMENT | April 2023 | June 2025 | Abandon | 26 | 1 | 1 | No | No |
| 18134875 | USE OF SGC ACTIVATORS FOR THE TREATMENT OF OPHTHALMOLOGIC DISEASES | April 2023 | February 2025 | Abandon | 22 | 2 | 1 | No | No |
| 18167783 | PHARMACEUTICAL COMPOSITIONS OF D10-DOCOSAHEXAENOIC ACID OR ESTERS THEREOF | February 2023 | April 2025 | Abandon | 26 | 2 | 1 | No | Yes |
| 18154505 | OPHTHALMOLOGICALLY SUITABLE LOW PKA BUFFER-CONTAINING PILOCARPINE COMPOSITIONS AND RELATED METHODS | January 2023 | March 2025 | Abandon | 26 | 3 | 1 | Yes | No |
| 17948376 | COMPOSITIONS, METHODS AND KITS FOR TREATING A CONTACT LENS | September 2022 | September 2024 | Allow | 24 | 1 | 1 | Yes | No |
| 17902124 | METHODS AND COMPOSITIONS TO INHIBIT SYMPTOMS ASSOCIATED WITH VEISALGIA | September 2022 | September 2024 | Abandon | 24 | 1 | 1 | No | No |
| 17817729 | PHARMACEUTICAL FORMULATIONS FOR SUBCUTANEOUS ADMINISTRATION OF FUROSEMIDE | August 2022 | March 2025 | Allow | 32 | 2 | 1 | Yes | No |
| 17817136 | 1-METHYL-1H-PYRAZOL-3-YL DERIVATIVES FOR USE IN THE TREATMENT OF NEOVASCULAR DISEASES | August 2022 | January 2024 | Allow | 17 | 2 | 1 | Yes | No |
| 17813221 | KETOROLAC TROMETHAMINE COMPOSITIONS FOR TREATING OR PREVENTING OCULAR PAIN | July 2022 | December 2023 | Abandon | 17 | 1 | 0 | No | No |
| 17736089 | METHODS FOR MODULATING CONDITIONS OF THE EYE USING NOVEL LATANOPROST COMPOUND OPHTHALMIC COMPOSITIONS | May 2022 | April 2024 | Abandon | 23 | 3 | 1 | No | No |
| 17736080 | STABLE LATANOPROST COMPOUND OPHTHALMIC COMPOSITIONS | May 2022 | February 2024 | Abandon | 22 | 3 | 1 | No | No |
| 17723079 | NICLOSAMIDE FORMULATIONS FOR TREATING DISEASE | April 2022 | December 2023 | Abandon | 19 | 1 | 0 | No | No |
| 17695410 | ORAL PHARMACEUTICAL COMPOSITION COMPRISING ZONISAMIDE AND PROCESS OF PREPARATION THEREOF | March 2022 | August 2022 | Allow | 5 | 0 | 1 | Yes | No |
| 17667418 | USE OF SGC ACTIVATORS FOR THE TREATMENT OF OPHTHALMOLOGIC DISEASES | February 2022 | June 2025 | Abandon | 40 | 1 | 1 | No | No |
| 17562487 | EXTENDED RELEASE PHARMACEUTICAL COMPOSITIONS OF RIOCIGUAT | December 2021 | March 2023 | Abandon | 14 | 1 | 1 | No | No |
| 17547028 | LIQUID DEPOT FOR NON-INVASIVE SUSTAINED DELIVERY OF AGENTS TO THE EYE | December 2021 | March 2025 | Allow | 39 | 4 | 1 | Yes | No |
| 17523648 | ALLERGEN DESENSITIZATION METHOD | November 2021 | November 2023 | Allow | 24 | 1 | 1 | Yes | No |
| 17509774 | EMULSION FORMULATIONS OF MULTIKINASE INHIBITORS | October 2021 | February 2023 | Allow | 15 | 2 | 1 | Yes | No |
| 17494635 | SAFE BRINZOLAMIDE AND BRIMONIDINE COMPOSITIONS WITH ENHANCED BENZALKONIUM CHLORIDE CONTENT | October 2021 | March 2023 | Abandon | 18 | 2 | 1 | No | No |
| 17494713 | SAFE USE OF BRINZOLAMIDE AND BRIMONIDINE COMPOSITIONS WITH ENHANCED BENZALKONIUM CHLORIDE CONTENT | October 2021 | May 2023 | Abandon | 19 | 3 | 0 | Yes | No |
| 17352698 | COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES | June 2021 | September 2024 | Abandon | 39 | 2 | 1 | No | No |
| 17330067 | NICLOSAMIDE FORMULATIONS FOR TREATING DISEASE | May 2021 | February 2022 | Allow | 9 | 1 | 1 | Yes | No |
| 17238045 | TARGETED ADMINISTRATION TO THE OROPHARYNX OF VISCOUS OR DRY POWDER FLUTICASONE PROPIONATE AND RELATED CORTICOSTEROIDS FOR THE TREATMENT OF EOSINOPHILIC ESOPHAGITIS (EoE) | April 2021 | June 2025 | Abandon | 49 | 0 | 1 | No | No |
| 17215856 | METHODS OF ACUTE RESTORATION OF VASCULAR COMPLIANCE | March 2021 | November 2023 | Abandon | 31 | 0 | 1 | No | No |
| 17205915 | OMEGA-3 PENTAENOIC ACID COMPOSITIONS AND METHODS OF USE | March 2021 | April 2025 | Abandon | 49 | 0 | 1 | No | No |
| 17274781 | 1-ISOPROPYL-3-METHYL-8-(PYRIDIN-3-YL)-1,3-DIHYDRO-2H-IMIDAZO[4,5-c]CINNOLIN-2-ONE AS SELECTIVE MODULATORS OF ATAXIA TELANGIECTASIA MUTATED (ATM) KINASE AND USES THEREOF | March 2021 | October 2024 | Allow | 44 | 0 | 1 | Yes | No |
| 17192379 | PROCESSES FOR MAKING CYCLIC LIPID IMPLANTS FOR INTRAOCULAR USE | March 2021 | March 2024 | Abandon | 36 | 1 | 1 | No | No |
| 17250756 | OPHTHALMIC COMPOSITIONS AND METHODS FOR THE TREATMENT OF EYE DISORDERS AND SKIN DISEASES | March 2021 | February 2025 | Abandon | 48 | 0 | 1 | No | No |
| 17180532 | PHARMACEUTICAL COMPOSITIONS OF ALPHA-2-ADRENERGIC RECEPTOR AGONISTS AND THEIR USE FOR IMPROVING VISION | February 2021 | April 2024 | Abandon | 38 | 0 | 1 | No | No |
| 17132246 | COMPOSITIONS FOR DELIVERY OF THERAPEUTICS INTO THE EYES AND METHODS FOR MAKING AND USING SAME | December 2020 | December 2024 | Abandon | 48 | 0 | 1 | No | No |
| 17251322 | METHODS AND COMPOSITIONS FOR TREATING AND/OR PREVENTING THE PROGRESSION AND/OR ONSET OF AGE-RELATED NEURODEGENERATION | December 2020 | June 2024 | Abandon | 43 | 0 | 1 | No | No |
| 17251559 | INHIBITORS OF EGFR AND METHODS OF USE THEREOF | December 2020 | August 2024 | Allow | 44 | 0 | 1 | Yes | No |
| 17097898 | NICLOSAMIDE FORMULATIONS FOR TREATING DISEASE | November 2020 | April 2021 | Allow | 5 | 0 | 1 | Yes | No |
| 17094986 | METHOD AND COMPOSITION FOR TREATING OCULAR HYPERTENSION AND GLAUCOMA | November 2020 | May 2024 | Abandon | 42 | 2 | 0 | No | No |
| 17053428 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR PROSTATE CANCER | November 2020 | January 2025 | Abandon | 51 | 2 | 0 | No | No |
| 17048586 | SYNTHESIS OF DENTIMOL, AN ANTIGLAUCOMA DRUG | October 2020 | May 2024 | Abandon | 43 | 0 | 1 | No | No |
| 17068954 | OCULAR FORMULATIONS FOR DRUG-DELIVERY AND PROTECTION OF THE ANTERIOR SEGMENT OF THE EYE | October 2020 | January 2024 | Abandon | 39 | 1 | 0 | No | No |
| 16998708 | METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATION | August 2020 | December 2022 | Allow | 27 | 1 | 0 | No | No |
| 16970292 | COMPOSITIONS FOR PREVENTING OR TREATING UVEITIS | August 2020 | November 2023 | Abandon | 39 | 0 | 1 | No | No |
| 16937444 | ALLERGEN DESENSITIZATION METHOD | July 2020 | October 2021 | Allow | 15 | 1 | 0 | No | No |
| 16960090 | METHOTREXATE OPHTHALMIC SOLUTION | July 2020 | August 2023 | Abandon | 38 | 1 | 0 | No | No |
| 16907310 | USE OF EMODIN IN TREATING RETINAL ISCHEMIA OR A DISEASE, CONDITION, OR DISORDER ASSOCIATED WITH RETINAL ISCHEMIA | June 2020 | February 2024 | Abandon | 43 | 2 | 1 | No | No |
| 16956033 | OMIDENEPAG COMBINATION | June 2020 | March 2024 | Abandon | 45 | 2 | 1 | No | No |
| 16892645 | COMPOSITIONS AND METHODS FOR NON-SURGICAL TREATMENT OF PTOSIS | June 2020 | July 2023 | Abandon | 38 | 2 | 0 | No | No |
| 16879484 | METHOD FOR INHIBITING OSTEOCLAST DEVELOPMENT | May 2020 | January 2023 | Allow | 32 | 2 | 0 | No | No |
| 16870898 | BROMODOMAIN INHIBITOR | May 2020 | February 2023 | Allow | 33 | 3 | 1 | Yes | No |
| 16869541 | LIPOIC ACID FORMULATIONS | May 2020 | January 2023 | Abandon | 33 | 0 | 1 | No | No |
| 16760663 | Pharmaceutical Compositions for Controlling and/or Reducing the Progression of Myopia | April 2020 | May 2025 | Abandon | 60 | 3 | 1 | No | No |
| 16863753 | Compositions and Methods for Treatment of Ocular Diseases | April 2020 | February 2022 | Allow | 22 | 2 | 1 | Yes | No |
| 16825898 | OPHTHALMIC FORMULATIONS AND USES THEREOF | March 2020 | June 2023 | Allow | 39 | 2 | 0 | Yes | No |
| 16806694 | KETOROLAC TROMETHAMINE COMPOSITIONS FOR TREATING OR PREVENTING OCULAR PAIN | March 2020 | September 2022 | Abandon | 30 | 1 | 0 | No | No |
| 16641621 | OCULAR PHARMACEUTICAL COMPOSITIONS | February 2020 | July 2023 | Allow | 41 | 2 | 1 | Yes | No |
| 16790035 | FORMULATION OF A RILUZOLE SOLUTION WITH BETA-CYCLODEXTRINS | February 2020 | October 2024 | Abandon | 56 | 3 | 1 | No | Yes |
| 16701602 | OPHTHALMIC FORMULATION AND METHOD FOR AMELIORATING PRESBYOPIA | December 2019 | January 2024 | Abandon | 49 | 4 | 1 | Yes | No |
| 16617173 | COMPOSITIONS AND METHODS FOR TREATING DRY EYE SYNDROME DELIVERING ANTIBIOTIC MACROLIDE | November 2019 | January 2024 | Abandon | 50 | 4 | 1 | No | No |
| 16686934 | JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES | November 2019 | May 2021 | Abandon | 18 | 1 | 0 | Yes | No |
| 16664179 | PHARMACOLOGY OF VISUAL CYCLE MODULATORS | October 2019 | October 2022 | Abandon | 36 | 2 | 0 | No | No |
| 16600732 | PROCESSES FOR MAKING CYCLIC LIPID IMPLANTS FOR INTRAOCULAR USE | October 2019 | August 2021 | Abandon | 22 | 1 | 1 | No | No |
| 16600553 | LUTEIN-CONTAINING OPHTHALMIC COMPOSITION | October 2019 | May 2022 | Allow | 31 | 1 | 0 | Yes | No |
| 16577262 | COMPOSITIONS AND METHODS FOR NON-SURGICAL TREATMENT OF PTOSIS | September 2019 | August 2020 | Allow | 11 | 2 | 1 | Yes | No |
| 16573384 | Methods and Compositions to Inhibit Symptoms Associated with Veisalgia | September 2019 | June 2022 | Allow | 32 | 1 | 1 | Yes | No |
| 16513103 | COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES | July 2019 | August 2021 | Abandon | 25 | 1 | 1 | No | No |
| 16476138 | OPHTHALMIC SOLUTION OF BIMATOPROST | July 2019 | September 2021 | Allow | 26 | 2 | 1 | Yes | No |
| 16399313 | PHOTOSTABLE ANTIOXIDANT COSMETIC COMPOSITION | April 2019 | March 2022 | Abandon | 35 | 1 | 1 | No | No |
| 16395206 | ALLERGEN DESENSITIZATION METHOD | April 2019 | April 2020 | Allow | 12 | 1 | 0 | Yes | No |
| 16373893 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY CONDITIONS | April 2019 | August 2021 | Abandon | 29 | 0 | 1 | No | No |
| 16335343 | PHOTOCHROMATIC MODULATION WITH FLUORESCEIN FOR THE TREATMENT OF PHOTO-OCULODYNIA AND BLEPHAROSPASM | March 2019 | April 2022 | Allow | 37 | 1 | 1 | Yes | No |
| 16334393 | DRUG DELIVERY SYSTEM FOR THE DELIVERY OF INTEGRASE INHIBITORS | March 2019 | June 2022 | Abandon | 38 | 2 | 1 | No | No |
| 16354764 | ORAL PHARMACEUTICAL COMPOSITION COMPRISING ZONISAMIDE AND PROCESS OF PREPARATION THEREOF | March 2019 | September 2022 | Allow | 42 | 2 | 1 | Yes | No |
| 16295085 | PHARMACEUTICAL FORMULATIONS FOR SUBCUTANEOUS ADMINISTRATION OF FUROSEMIDE | March 2019 | April 2022 | Allow | 38 | 2 | 1 | No | No |
| 16317101 | METHODS AND POLYMER COMPOSITIONS FOR TREATING RETINAL DETACHMENT AND OTHER OCULAR DISORDERS | January 2019 | March 2021 | Abandon | 26 | 0 | 1 | No | No |
| 16240578 | METHODS FOR THE TREATMENT AND PREVENTION OF AGE-RELATED RETINAL DYSFUNCTION | January 2019 | October 2020 | Abandon | 22 | 0 | 1 | No | No |
| 16184834 | Sustained-Release Implants for Lowering Intraocular Pressure with Extended Duration of Effect | November 2018 | June 2023 | Abandon | 55 | 3 | 0 | No | Yes |
| 16183562 | OPHTHALMIC PREPARATIONS | November 2018 | September 2021 | Allow | 34 | 4 | 1 | Yes | No |
| 16183593 | OPHTHALMIC PREPARATIONS | November 2018 | December 2021 | Allow | 38 | 5 | 1 | Yes | No |
| 16181763 | OPHTHALMIC DEVICES FOR DELIVERY OF HYDROPHOBIC COMFORT AGENTS | November 2018 | October 2020 | Allow | 23 | 0 | 1 | Yes | No |
| 16096603 | Compositions, Methods and Kits for Treating a Contact Lens | October 2018 | August 2022 | Allow | 45 | 3 | 1 | Yes | No |
| 16095593 | METHODS, COMPOSITIONS AND USES RELATING THERETO | October 2018 | December 2021 | Allow | 38 | 2 | 1 | Yes | No |
| 16089715 | STORAGE-STABLE OPHTHALMIC COMPOSITION | September 2018 | December 2021 | Allow | 38 | 4 | 1 | Yes | Yes |
| 15780828 | USE OF ENZYME-MODIFIED ISOQUERCITRIN | August 2018 | February 2021 | Abandon | 32 | 1 | 1 | No | No |
| 16036919 | ALLERGEN DESENSITIZATION METHOD | July 2018 | December 2018 | Allow | 5 | 1 | 0 | No | No |
| 16010739 | METHOD AND COMPOSITION FOR TREATING OCULAR HYPERTENSION AND GLAUCOMA | June 2018 | August 2020 | Allow | 26 | 2 | 0 | No | No |
| 15968358 | THERAPEUTIC REGIMEN AND METHODS FOR TREATING OR AMELIORATING VISUAL DISORDERS ASSOCIATED WITH AN ENDOGENOUS RETINOID DEFICIENCY | May 2018 | December 2020 | Abandon | 31 | 1 | 1 | No | No |
| 15962545 | METHOD OF USING A COMPOSITION FOR ENHANCING NEWBORN INFANT COGNITIVE, BRAIN AND/OR CNS DEVELOPMENT | April 2018 | April 2020 | Allow | 24 | 1 | 1 | Yes | No |
| 15877865 | PHARMACEUTICAL FORMULATIONS FOR SUBCUTANEOUS ADMINISTRATION OF FUROSEMIDE | January 2018 | February 2019 | Allow | 12 | 1 | 0 | Yes | No |
| 15849557 | FORMULATIONS OF TOCOTRIENOL QUINONES FOR THE TREATMENT OF OPHTHALMIC DISEASES | December 2017 | October 2018 | Abandon | 10 | 0 | 1 | No | No |
| 15839784 | METHODS FOR THE TREATMENT AND PREVENTION OF AGE-RELATED RETINAL DYSFUNCTION | December 2017 | March 2019 | Abandon | 15 | 1 | 1 | No | No |
| 15837325 | Compositions and Methods for Non-Surgical Treatment of Ptosis | December 2017 | October 2020 | Abandon | 34 | 2 | 0 | No | No |
| 15579030 | MOSQUITO VECTOR CONTROL COMPOSITIONS, METHODS AND PRODUCTS UTILIZING SAME | December 2017 | August 2023 | Allow | 60 | 2 | 1 | Yes | Yes |
| 15807282 | METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATION | November 2017 | February 2020 | Allow | 27 | 2 | 1 | No | No |
| 15807166 | METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATION | November 2017 | June 2020 | Allow | 32 | 3 | 1 | Yes | No |
| 15807235 | METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATION | November 2017 | May 2020 | Abandon | 30 | 2 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner HUANG, GIGI GEORGIANA.
With a 16.7% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 9.4% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner HUANG, GIGI GEORGIANA works in Art Unit 1613 and has examined 189 patent applications in our dataset. With an allowance rate of 39.2%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 38 months.
Examiner HUANG, GIGI GEORGIANA's allowance rate of 39.2% places them in the 4% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by HUANG, GIGI GEORGIANA receive 2.80 office actions before reaching final disposition. This places the examiner in the 92% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by HUANG, GIGI GEORGIANA is 38 months. This places the examiner in the 11% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +60.2% benefit to allowance rate for applications examined by HUANG, GIGI GEORGIANA. This interview benefit is in the 97% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 10.9% of applications are subsequently allowed. This success rate is in the 2% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 19.0% of cases where such amendments are filed. This entry rate is in the 15% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants request a pre-appeal conference (PAC) with this examiner, 20.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 25% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 45.5% of appeals filed. This is in the 8% percentile among all examiners. Of these withdrawals, 40.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 44.9% are granted (fully or in part). This grant rate is in the 49% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 0% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 0% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.